Meeting
2021 ASCO Annual Meeting
Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.
Authors
Jaleh Fallah
U.S. Food and Drug Administration, Silver Spring, MD
Jaleh Fallah , Haley Gittleman , Chana Weinstock , Erik Bloomquist , Elaine Chang , Daniel L. Suzman , Sundeep Agrawal , Amna Ibrahim , Shenghui Tang , Richard Pazdur , Julia A. Beaver , Laleh Amiri-Kordestani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4516)
DOI
10.1200/JCO.2021.39.15_suppl.4516
Abstract #
4516
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.
First Author: Sara Elena Rebuzzi
Poster
2024 ASCO Genitourinary Cancers Symposium
Optimal timing of delayed cytoreductive nephrectomy in metastatic renal cell carcinoma during the immunotherapy era.
First Author: Insija Ilyas Selene
Poster
2023 ASCO Genitourinary Cancers Symposium
Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
First Author: Sally Leong
Poster
2021 ASCO Annual Meeting
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Chun Loo Gan